Plasma transfusions are given to people whose blood cannot clot properly, either because of a medical condition, a medication, or massive blood loss. The core reason is always the same: the patient is missing critical clotting factors and is either actively bleeding or at serious risk of bleeding. Outside of a few specific diseases, plasma is not used as a general treatment or fluid replacement.
Trauma Patients With Major Blood Loss
The most common emergency use of plasma is in trauma patients who need a massive transfusion, generally defined as receiving ten or more units of red blood cells within 24 hours. When you lose that much blood, you lose clotting factors along with it, and your body can no longer form stable clots on its own. Hospitals activate what’s called a massive transfusion protocol, delivering plasma alongside red blood cells and platelets to approximate whole blood.
The ideal ratio of plasma to red blood cells in these situations is still debated, but a large multicenter study found that a ratio between roughly 1:2 and 1:1 in the first 72 hours improved survival. Many trauma centers aim for a 1:1 ratio in the most critically injured patients. The Association for the Advancement of Blood & Biotherapies (AABB) recommends plasma for trauma patients requiring massive transfusion, though it stops short of endorsing a specific ratio due to limited evidence.
People Taking Warfarin Who Develop Bleeding
Warfarin is a blood thinner that works by suppressing several clotting factors. If someone on warfarin develops serious bleeding, particularly bleeding inside the skull, those clotting factors need to be restored fast. Plasma contains the exact factors that warfarin suppresses (factors II, VII, IX, and X), making it one option for emergency reversal. The AABB specifically recommends plasma for warfarin-related bleeding in the brain. For other types of warfarin-related bleeding, the evidence is weaker, and newer concentrated clotting products are often preferred when available because they work faster and require less fluid volume.
One important distinction: plasma should not be used to reverse heparin, a different type of blood thinner. Heparin works through a completely different mechanism, and plasma will not counteract it.
Liver Disease and Clotting Problems
The liver manufactures most of the body’s clotting factors, so advanced liver disease often leads to abnormal clotting tests. In one study of plasma use, coagulopathy with an elevated INR (a measure of how long blood takes to clot) was the most common reason for transfusion, accounting for over 55% of cases. Most of those patients had an INR above 1.5, with the median sitting at 2.49.
That said, plasma transfusion for liver disease is more complicated than it appears. Research shows it has minimal effect at bringing the INR below 1.7, and the American Association for the Study of Liver Diseases actually advises against using plasma to “correct” the INR before procedures like liver biopsy. The elevated INR in liver disease doesn’t predict bleeding risk the same way it does in other conditions. Plasma is most useful when a liver disease patient is actively bleeding, not as a preventive measure before a procedure.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC) is a dangerous condition where clotting goes haywire throughout the body. Small clots form in blood vessels everywhere, using up clotting factors and platelets so rapidly that the body can’t keep up. The result is a paradox: widespread clotting and uncontrolled bleeding happening at the same time. DIC isn’t a disease on its own but a complication of something else, such as severe infection, cancer, or pregnancy complications.
Plasma transfusion replaces the multiple clotting factors being consumed all at once. It plays a particularly important role in DIC triggered by obstetric emergencies, where low fibrinogen (a key clotting protein) is a hallmark. For severe postpartum hemorrhage, the International Federation of Gynecology and Obstetrics recommends massive transfusion protocols that combine red blood cells, plasma, and platelets.
Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening blood disorder that uses plasma in a unique way. In TTP, the body either doesn’t produce enough of a specific enzyme called ADAMTS13 or produces antibodies that attack it. This enzyme normally breaks down an extra-sticky form of a clotting protein. Without it, tiny clots form spontaneously throughout the smallest blood vessels, damaging organs and destroying red blood cells in the process. The classic signs include very low platelet counts, anemia, fever, confusion, and kidney problems.
The treatment for TTP is plasma exchange, not just a simple transfusion. During plasma exchange, the patient’s plasma is removed and replaced with donor plasma. This accomplishes two things at once: it delivers the missing enzyme and removes the harmful antibodies and sticky clotting proteins causing the damage. A landmark 1991 trial found that plasma exchange reduced mortality to about 4% during the initial treatment period, compared to nearly 16% for patients receiving plasma infusion alone. That survival benefit held at six months, and plasma exchange has been the standard of care ever since.
Rare Clotting Factor Deficiencies
For most inherited bleeding disorders, concentrated versions of the missing clotting factor are available as standalone treatments, and those are preferred over plasma. But factor V deficiency is the one exception: no concentrated product exists for it. People with factor V deficiency who are actively bleeding, or who need protection before surgery, receive plasma as their primary treatment.
Plasma may also be used for people with congenital protein C deficiency (a natural anticoagulant the body needs) when specific replacement products aren’t available. In resource-limited settings where concentrated factor products are hard to access, plasma serves as a broader backup for various clotting factor deficiencies, though it’s always a second-choice option when concentrates exist.
When Plasma Is Not Appropriate
Plasma is sometimes ordered in situations where it provides little or no benefit. A mildly abnormal clotting test alone, without active bleeding or a planned high-risk procedure, is generally not a good reason for transfusion. At many hospitals, plasma orders are approved when the INR exceeds 1.5, but borderline elevations above that threshold don’t reliably predict bleeding and often aren’t meaningfully corrected by plasma.
Plasma is also not a volume expander. If someone simply needs more fluid in their bloodstream, saline or other non-blood products work just as well without the risks that come with a blood product, including allergic reactions, fluid overload, and transfusion-related lung injury. It should not be used as a nutritional supplement for patients with low protein levels, and it has no role in reversing heparin-based blood thinners. Every unit carries real risks, so the clinical bar for giving it should be clear: missing clotting factors, active or imminent bleeding, and no better alternative available.